Glax­o­SmithK­line, Ox­ford un­veil new part­ner­ship pit­ting buzzy R&D ad­vances against neu­ro­log­i­cal dis­ease

When Glax­o­SmithK­line trum­pet­ed its re­turn to neu­ro­science with a $700 mil­lion up­front deal with Alec­tor this sum­mer, it tout­ed its ear­ly in­vest­ments in func­tion­al ge­nomics as a key guide­post for that deal. Now, the drug gi­ant has part­nered up with Ox­ford to hope­ful­ly add jet fu­el to its hunt for break­throughs in the brain.

GSK and Ox­ford have kick­start­ed a five-year col­lab­o­ra­tion aimed at spurring R&D break­throughs across a range of hard-to-treat dis­eases like Alzheimer’s and Parkin­son’s through the use of ge­nom­ic test­ing and ma­chine learn­ing, the part­ners said Wednes­day.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN